CEDARHURST, N.Y., March 17, 2019 (GLOBE NEWSWIRE)
-- The securities litigation law firm of Kuznicki Law PLLC issues
the following notice on behalf of shareholders of the following
publicly traded companies. Shareholders who purchased shares in
these companies during the dates listed below are encouraged to
contact the firm regarding possible appointment as lead plaintiff
and a preliminary estimate of their recoverable losses.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.
DBV Technologies S.A. (DBVT)
Investors Affected: February 14, 2018 - December 19,
2018
A class action has commenced on behalf of certain shareholders in DBV Technologies SA. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DBV Technologies' Biologics License Application ("BLA") for Viaskin Peanut failed to provide the FDA with sufficient data on manufacturing procedures and quality controls; (2) consequently, DBV Technologies voluntarily withdrew the BLA for Viaskin Peanut; and (3) as a result, defendants' statements about DBV Technologies' business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
Shareholders may find more information at https://kseclaw.com/securities/dbv-technologies-s-a/?wire=3
Amarin Corporation (AMRN)
Investors Affected: September 24, 2018 - November 9,
2018
A class action has commenced on behalf of certain shareholders in Amarin Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://kclasslaw.com/securities/amarin-corporation-loss-submission-form/?wire=3
Weight Watchers International, Inc.
(WTW)
Investors Affected: May 4, 2018 - February 26,
2019
A class action has commenced on behalf of certain shareholders in Weight Watchers International, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) Weight Watchers was experiencing diminished subscriber demand attributable due to the onslaught of new competing smartphone fitness apps, meal-delivery services, and other tech advances was driving down Weight Watchers’ new subscriber growth and its subscriber retention rates; (b) diminished subscriber growth, when coupled with the much larger number of fourth quarter subscription lapses that Weight Watchers typically experiences, made it highly unlikely that the Company would retain four million subscribers by the end of 2018; (c) Weight Watchers was not on track to grow its subscriber count to five million or to drive annual revenues to more than $2 billion by the end-of-2020; (d) a decreased subscriber count would result in decreased revenues and profits; and (e) as a result, Defendants’ statements about Weight Watchers’ business metrics and financial prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Shareholders may find more information at https://kclasslaw.com/securities/weight-watchers-international-inc-loss-submission-form/?wire=3
Corbus Pharmaceutical Holdings, Inc.
(CRBP)
Investors Affected: November 14, 2016 - February 28,
2019
A class action has commenced on behalf of certain shareholders in Corbus Pharmaceutical Holdings, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Shareholders may find more information at https://kclasslaw.com/securities/corbus-pharmaceutical-holdings-inc-loss-submission-form/?wire=3
Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock.
CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: [email protected]
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967